carvedilol Side Effects
Also known as: Coreg
Analysis of 130,791 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
130,791
Death-Related
15,919
12.2% of reports
Hospitalizations
53,070
40.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 15,919 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 5,616 |
| COMPLETED SUICIDE | 1,202 |
| RENAL FAILURE | 1,049 |
| CARDIAC FAILURE CONGESTIVE | 1,030 |
| DYSPNOEA | 869 |
| PNEUMONIA | 868 |
| CARDIAC ARREST | 855 |
| ACUTE KIDNEY INJURY | 799 |
| CARDIAC FAILURE | 735 |
| HYPOTENSION | 710 |
| CHRONIC KIDNEY DISEASE | 665 |
| MYOCARDIAL INFARCTION | 659 |
| ASTHENIA | 596 |
| CARDIO-RESPIRATORY ARREST | 585 |
| RESPIRATORY FAILURE | 571 |
| FATIGUE | 560 |
| GASTROINTESTINAL HAEMORRHAGE | 535 |
| SEPSIS | 533 |
| FALL | 532 |
| TOXICITY TO VARIOUS AGENTS | 520 |
Reactions in Hospitalization Reports
Top reactions in 53,070 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 4,434 |
| CARDIAC FAILURE CONGESTIVE | 3,622 |
| PNEUMONIA | 3,344 |
| HYPOTENSION | 3,313 |
| FATIGUE | 3,000 |
| FALL | 2,876 |
| ASTHENIA | 2,781 |
| MYOCARDIAL INFARCTION | 2,733 |
| NAUSEA | 2,666 |
| DIARRHOEA | 2,663 |
| ACUTE KIDNEY INJURY | 2,525 |
| DIZZINESS | 2,511 |
| ANAEMIA | 2,290 |
| GASTROINTESTINAL HAEMORRHAGE | 2,252 |
| RENAL FAILURE | 2,097 |
| VOMITING | 2,050 |
| CARDIAC FAILURE | 1,953 |
| CHEST PAIN | 1,835 |
| HYPERTENSION | 1,776 |
| PAIN | 1,763 |
Nearby — Related Medications
What the FAERS Data Reveals About carvedilol Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 130,791 voluntary reports linked to carvedilol and its brand equivalents (Coreg), spanning 2003 through 2025. Of those, 15,919 (12.2%) listed death as an outcome and 53,070 (40.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 47% were female and 53% male; age distribution skews toward 45-64, with 28,089 reports in that bracket. The single most reported reaction is fatigue with 8,669 submissions, followed by dyspnoea and diarrhoea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.